Blocking NF-κB signals by inhibitors of interleukin-1 receptor-associated kinase 1/4 (IRAK1/4 inhibitors) together with imatinib eliminates mouse and human CML LSCs. This evidence concerns the gene NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive.